ClinicalTrials.gg

Program

Tirzepatide

Also written as “Arm 5- Tirzepatide”, “Tirzepatide Dose 1” and “Tirzepatide Dose 2”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus, Type 1 · Psoriasis · Non-alcoholic Fatty Liver Disease, led by 4 companies.

Furthest: phase 4, since Jun 22, 202272 company-led studies, 20 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly6918 open or runningphase 4since Jun 22, 2022Apr 29, 2016Nov 2026phase 1 · NCT07299084
Florida Academic Centers Research and Education11 open or runningno phasesince Mar 1, 2024Mar 1, 2024none ahead
Hudson Biotech11 open or runningphase 3since Mar 8, 2026Mar 8, 2026Feb 14, 2027phase 3 · NCT07481747
Lexaria Bioscience10 open or runningphase 1since Oct 16, 2024Oct 16, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 43 studies since May 15, 2019.

  1. Oct 4, 2024Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT06635057 · 166 enrolled · Saudi Arabia, United Arab Emirates
  2. Oct 14, 2024Phase 2 study in ObesityEli Lilly · NCT06643728 · 252 enrolled · United States
  3. Oct 16, 2024Lexaria Bioscience's first study: phase 1 study in Type2diabetesNew to Lexaria BioscienceLexaria Bioscience · NCT06648031 · 148 enrolled · Australia
  4. Mar 3, 20252 phase 4 studiesEli Lilly · NCT06864026, NCT06857942
  5. Mar 24, 2025Phase 2 study in ObesityEli Lilly · NCT06901349 · United States, Argentina, Canada and more
  6. Apr 4, 20253 phase 3 studiesEli Lilly · NCT06914895, NCT06937099, NCT06937086
  7. May 6, 2025Phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT06962280 · 465 enrolled · United States, Argentina, Brazil and more
  8. Aug 28, 2025Phase 3 study in Non-alcoholic Fatty Liver DiseaseEli Lilly · NCT07165028 · 4,500 planned · United States, Argentina, Australia and more
  9. Nov 19, 2025Phase 4 study in ObesityEli Lilly · NCT07247084 · 3,000 planned · United Kingdom
  10. Dec 10, 2025Phase 1 study in Diabetes Mellitus, Type 2Eli Lilly · NCT07299084 · 40 enrolled · Singapore
  11. Feb 23, 2026Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT07438444 · 344 enrolled · India
  12. Mar 8, 2026Hudson Biotech's first study: phase 3 study in ObesityNew to Hudson BiotechHudson Biotech · NCT07481747 · 2,539 planned · China
  13. Sep 1, 2026Phase 1 study in Diabetes Mellitus, Type 1Eli Lilly · NCT07803744 · 18 planned · United States
  14. Sep 9, 2026Phase 3 study in ObesityEli Lilly · NCT07817875 · 150 planned · United States, Belgium, Israel and more

Ahead

  1. Nov 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 2Eli Lilly · NCT07299084
  2. Nov 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT06962280
  3. Nov 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT06914895
  4. Dec 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 1Eli Lilly · NCT07803744

TargetBeta

GIPR →GLP1R →read by rule
“Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
retatrutideruleEli Lillyphase 333
olatorepatideHansoh Pharmaceutical Groupphase 312
UBT251The United Laboratories Internationalphase 312
enicepatideHoffmann-La Rochephase 310
VK2735ruleViking Therapeuticsphase 38
NNC0519-0130Novo Nordiskphase 211
BI 3034701Boehringer Ingelheimphase 26
HRS-4729Jiangsu HengRui Medicinephase 25
NA-931rulebiomed-industries-incphase 23

Studies

The newest 60 of 72 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07817875Obesity · United States, Belgium, Israel and more3RecruitingEli LillyDec 2029150
NCT07803744Diabetes Mellitus, Type 1 · United States1RecruitingEli LillyDec 202618
NCT07481747Obesity · China3RecruitingHudson BiotechFeb 14, 20272,539
NCT07438444Diabetes Mellitus, Type 2 · India4Active, not recruitingEli LillyJul 2027344
NCT07299084Diabetes Mellitus, Type 2 · Singapore1Active, not recruitingEli LillyNov 202640
NCT07247084Obesity · United Kingdom4RecruitingEli LillyJul 20293,000
NCT07165028Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3RecruitingEli LillyAug 20304,500
NCT06962280Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more3Active, not recruitingEli LillyNov 2026465
NCT06937099Crohn Disease · United States, Austria, Belgium and more3RecruitingEli LillyMay 2028290
NCT06937086Colitis, Ulcerative · United States, Austria, Belgium and more3RecruitingEli LillyApr 2028350
NCT06914895Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more3Active, not recruitingEli LillyNov 2026905
NCT06901349Obesity · United States, Argentina, Canada and more2WithdrawnEli LillyJun 10, 20250
NCT06864026Arthritis, Psoriatic · United States, Puerto Rico4Active, not recruitingEli LillyAug 2027200
NCT06857942Psoriasis · United States4RecruitingEli LillyMay 2028200
NCT06648031Type2diabetes · Australia1CompletedLexaria BioscienceJul 31, 2025148
NCT06643728Obesity · United States2Active, not recruitingEli LillyJan 16, 2026252
NCT06635057Diabetes Mellitus, Type 2 · Saudi Arabia, United Arab Emirates4CompletedEli LillyApr 15, 2026166
NCT06588296Arthritis, Psoriatic · United States, Puerto Rico3CompletedEli LillyNov 18, 2025279
NCT06588283Psoriasis · United States, Puerto Rico3CompletedEli LillyJan 8, 2026281
NCT06439277Obesity · United States, Argentina, Australia and more3RecruitingEli LillyOct 2027300
NCT06301256Hidradenitis Suppurativa–Not yet recruitingFlorida Academic Centers Research and EducationMar 11, 202520
NCT06075667Obesity · United States, Canada, Czechia and more3Active, not recruitingEli LillyJun 2, 2026160
NCT06047548Overweight · United States3CompletedEli LillyJan 20, 2026441
NCT06037252Diabetes Mellitus, Type 2 · United States, Argentina, Mexico and more2Active, not recruitingEli LillyJan 8, 2026414
NCT05978713Healthy · United States1CompletedEli LillyMar 12, 202411
NCT05963022Diabetes Mellitus, Type 2 · China3CompletedEli LillyOct 9, 2024206
NCT05810597Healthy · United States1CompletedEli LillyJul 17, 202365
NCT05706506Diabetes Mellitus, Type 2 · United States4CompletedEli LillyOct 31, 2023152
NCT05696847Obesity · United States1CompletedEli LillyJan 16, 202528
NCT05691712Diabetes Mellitus, Type 2 · China3CompletedEli LillyJul 1, 2024257
NCT05564039Diabetes Mellitus, Type 2 · United States, Belgium, Germany and more4CompletedEli LillyJul 15, 2024282
NCT05556512Obesity · United States, Argentina, Australia and more3Active, not recruitingEli LillyOct 202715,374
NCT05822830Obesity · United States, Puerto Rico3CompletedEli LillyNov 13, 2024751
NCT05536804Overweight · United States, Austria, Canada and more2CompletedEli LillyJul 6, 2026134
NCT05433584Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more4Active, not recruitingEli LillyOct 21, 2025794
NCT05412004Sleep Apnea, Obstructive · United States, Australia, Brazil and more3CompletedEli LillyMar 12, 2024469
NCT05260021Diabetes Mellitus · United States, Australia, Brazil and more3CompletedEli LillyJul 30, 202499
NCT05024032Obesity · China3CompletedEli LillyDec 27, 2022210
NCT04844918Obesity · Japan3CompletedEli LillyJun 24, 2023267
NCT04847557Obesity · United States, Argentina, Brazil and more3CompletedEli LillyJul 2, 2024731
NCT04660643Obesity · United States, Argentina, Brazil and more3CompletedEli LillyApr 25, 2023783
NCT04657016Obesity · United States, Argentina, Brazil and more3CompletedEli LillyApr 20, 2023579
NCT04657003Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3CompletedEli LillyMar 16, 2023938
NCT04537923Diabetes Mellitus, Type 2 · United States, Argentina, Belgium and more3CompletedEli LillyOct 11, 20221,428
NCT04407234Overweight · United States1CompletedEli LillyJan 7, 202136
NCT04311424Healthy · United Kingdom1CompletedEli LillyOct 2, 20206
NCT04311411Obesity · United States1CompletedEli LillyDec 16, 2022114
NCT04255433Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedEli LillyJun 12, 202513,299
NCT04235959Diabetes Mellitus, Type 2 · China1CompletedEli LillyAug 17, 202124
NCT04184622Overweight · United States, Argentina, Brazil and more3CompletedEli LillyApr 1, 20222,539
NCT04172987Healthy · United States1CompletedEli LillyFeb 9, 202140
NCT04166773Non-alcoholic Fatty Liver Disease · United States, Belgium, France and more2CompletedEli LillyDec 11, 2023190
NCT04093752Diabetes Mellitus, Type 2 · Australia, China, India and more3CompletedEli LillyNov 1, 2021917
NCT04081337Obesity · United States1CompletedEli LillyMay 26, 202255
NCT04050670Healthy · United States1CompletedEli LillyApr 3, 202054
NCT04050553Diabetes Mellitus, Type 2 · Austria1CompletedEli LillyJan 25, 202242
NCT04039503Diabetes Mellitus, Type 2 · United States, Czechia, Germany and more3CompletedEli LillyDec 22, 2020475
NCT04004988Healthy · Singapore1CompletedEli LillyDec 16, 201947
NCT03987919Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedEli LillyJan 28, 20211,879
NCT03954834Diabetes Mellitus, Type 2 · United States, India, Japan and more3CompletedEli LillyOct 5, 2020478

How it is read

Names in the registry

  • “Tirzepatide”, 69 entries
  • “Arm 5- Tirzepatide”, 1 entry
  • “Tirzepatide Dose 1”, 1 entry
  • “Tirzepatide Dose 2”, 1 entry
  • “TIRZEPATIDE”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.